<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02297048</url>
  </required_header>
  <id_info>
    <org_study_id>P120906</org_study_id>
    <nct_id>NCT02297048</nct_id>
  </id_info>
  <brief_title>Monocentric STUDY, Randomised Double Blinded (Healthy Subjects, or Transversal (Patients With Gitelman Syndrome)</brief_title>
  <acronym>DEPROGE</acronym>
  <official_title>Monocentric STUDY, Randomised Double Blinded (Healthy Subjects, or Transversal (Patients With Gitelman Syndrome)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Progesterone is needed to permit adaptation of the kidney to limit potassium loss in the&#xD;
      urines. The investigators wonder whether progesterone or other adrenal hormon play the same&#xD;
      role. The investigators will investigate surrenal hormone production in healthy subjects&#xD;
      under a 7-day potassium depleted diet and in patients chronically hypokalaemic due to a renal&#xD;
      loss of potassium.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will study the adaptation of steroidogenesis to potassium depletion in&#xD;
      healthy volunteer, and the role of progesterone in renal adaptation to potassium depletion.&#xD;
      Practically, healthy volunteers will be submitted twice to two periods of normal Na+/ high K+&#xD;
      diet (control period) followed by a normal Na+/ low K+ diet sustained by a pharmacological&#xD;
      treatment with Kayexalate (K+-depleted condition). The subjects will be treated with either&#xD;
      RU486 or a placebo, according to a randomization. The adrenal response will be evaluated&#xD;
      after stimulation by Synacthen at baseline and at the end of each experimental period. A&#xD;
      Synacthen test will be also done in 10 patients suffering of chronic hypokalemia linked to a&#xD;
      hereditary tubulopathy inducing renal K+ leak called Gitelman syndrome and their plasma&#xD;
      steroid profile will be established.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of potassium depletion on plasma progesterone (Change from Baseline of progesterone)</measure>
    <time_frame>Day 1 and Day 8 of placebo period of treatment (healthy subjects) or once (Gitelman patients)</time_frame>
    <description>Healthy subjects : Change from Baseline of progesterone in response to synacthen at day 8 in subject treated by placebo.&#xD;
Patients with Gitelman syndrome: Change from Baseline of progesterone in response to synacthen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>effect of RU 486 on renal adaptation to potassium depletion (Plasma potassium and kaliuresis will be monitored )</measure>
    <time_frame>Day 1 and day 8 of each period of treatment</time_frame>
    <description>Plasma potassium and kaliuresis will be monitored during the 7-days potassium depletion in subjects treated by RU486 or placebo, according randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of potassium depletion on pulse pressure velocity (Pulse wave velocity and central blood pressure)</measure>
    <time_frame>At Day 1 and Day 8 of each period of treatment</time_frame>
    <description>Pulse wave velocity and central blood pressure are measured before and after 7 days of potassium deprivated diet.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of potassium depletion on plasma progesterone under RU486 (Change from Baseline of progesterone)</measure>
    <time_frame>Day 1 and Day 8 of placebo period of treatment (healthy subjects) or once (Gitelman patients)</time_frame>
    <description>Healthy subjects : Change from Baseline of progesterone in response to synacthen at day 8 in subject treated by RU486.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Gitelman Syndrome</condition>
  <condition>Potassium Depletion</condition>
  <arm_group>
    <arm_group_label>RU 486 (mifepristone)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 400 mg once a day of RU486</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Potassium depletion</intervention_name>
    <description>Healthy subjects will be submitted twice at 15-30 day interval, to a low potassium diet (20mmol/day)</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>RU 486 (mifepristone)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for healthy subjects:&#xD;
&#xD;
          -  Caucasian male subject&#xD;
&#xD;
          -  18-35 yrs-old&#xD;
&#xD;
          -  BMI between 18 and 30 Kg/m2&#xD;
&#xD;
          -  Normal biological pattern (sodium, potassium, eGFR &gt;60mL/min/1.73 m2, SGOT and SGPT &lt;&#xD;
             2.5 normal value)&#xD;
&#xD;
          -  Non smoker subjects or less than 5 cigarettes a day&#xD;
&#xD;
          -  No drug abuse&#xD;
&#xD;
          -  No active viral B or C hepatitis, no positive HIV serology&#xD;
&#xD;
          -  No treatment except paracetamol&#xD;
&#xD;
          -  Normal EKG&#xD;
&#xD;
          -  Inform consent given&#xD;
&#xD;
          -  Affiliation to French Medicare assurance&#xD;
&#xD;
        Inclusion Criteria for patients :&#xD;
&#xD;
          -  18-75 Years old subjects&#xD;
&#xD;
          -  genetically proven Gitelman syndrome&#xD;
&#xD;
          -  Normal EKG&#xD;
&#xD;
          -  Inform consent given&#xD;
&#xD;
          -  Affiliation to French Medicare assurance&#xD;
&#xD;
        Non inclusion Criteria for healthy subjects:&#xD;
&#xD;
          -  History of cardiac arrythmia or abnormal EKG&#xD;
&#xD;
          -  Recent or chronic diarrhea&#xD;
&#xD;
          -  Spontaneous low potassium intakes&#xD;
&#xD;
          -  Biological abnormality : SGOT or SGPT &gt; 2.5 N, fasting hyperglycemia (&gt; 6.5 mmol/l,&#xD;
             anemia (hemoglobin&lt; 12g/dL)&#xD;
&#xD;
          -  Single or functionally solitary kidney&#xD;
&#xD;
          -  Any severe allergies, or allergic history to any drug.&#xD;
&#xD;
          -  Predicted Difficulty monitoring and compliance.&#xD;
&#xD;
          -  Blood donation for less than 2 months.&#xD;
&#xD;
          -  Persons directly involved in the implementation of the Protocol.&#xD;
&#xD;
          -  Person in exclusion period in biomedical research.&#xD;
&#xD;
          -  Protected Person (person under guardianship, deprived of liberty, ...).&#xD;
&#xD;
          -  Taking medication in the previous 7 days (except paracetamol).&#xD;
&#xD;
          -  Chronic adrenal insufficiency.&#xD;
&#xD;
          -  Known allergy to any of the excipients of the RU 486 (colloidal anhydrous silica,&#xD;
             maize starch, povidone, microcrystalline cellulose, magnesium stearate).&#xD;
&#xD;
          -  Severe asthma not controlled by treatment.&#xD;
&#xD;
          -  Porphyria hereditary.&#xD;
&#xD;
        Non inclusion Criteria for Gitelman patients:&#xD;
&#xD;
          -  People that did not give their consent or unable to understand the protocol.&#xD;
&#xD;
          -  Anemia (Hg &lt;10 g / dL).&#xD;
&#xD;
          -  Clinically significant abnormality on the EKG.&#xD;
&#xD;
          -  Any severe allergies, or allergic history to any drug.&#xD;
&#xD;
          -  Treatment with corticosteroids.&#xD;
&#xD;
          -  Patient in exclusion period in biomedical research.&#xD;
&#xD;
          -  Protected Person (patient trust, deprived of liberty, ...)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Blanchard, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>European George Pompidou Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Elabida B, Edwards A, Salhi A, Azroyan A, Fodstad H, Meneton P, Doucet A, Bloch-Faure M, Crambert G. Chronic potassium depletion increases adrenal progesterone production that is necessary for efficient renal retention of potassium. Kidney Int. 2011 Aug;80(3):256-62. doi: 10.1038/ki.2011.15. Epub 2011 Feb 16.</citation>
    <PMID>21326170</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>October 29, 2014</study_first_submitted>
  <study_first_submitted_qc>November 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2014</study_first_posted>
  <last_update_submitted>September 30, 2015</last_update_submitted>
  <last_update_submitted_qc>September 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Potassium intake</keyword>
  <keyword>Progesterone</keyword>
  <keyword>steroidogenesis</keyword>
  <keyword>RU486</keyword>
  <keyword>Synachtene test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gitelman Syndrome</mesh_term>
    <mesh_term>Hypokalemia</mesh_term>
    <mesh_term>Potassium Deficiency</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

